Total Payments
$1.5M
2024 Payments
$151,663
Companies
21
Transactions
1,791
Medicare Patients
458
Medicare Billing
$46,655
Payment Breakdown by Category
Other$1.0M (71.3%)
Consulting$200,180 (13.8%)
Travel$179,040 (12.3%)
Food & Beverage$32,397 (2.2%)
Research$4,753 (0.3%)
Education$109.14 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 455 | 70.5% |
| Consulting Fee | $200,180 | 76 | 13.8% |
| Travel and Lodging | $179,040 | 570 | 12.3% |
| Food and Beverage | $32,397 | 675 | 2.2% |
| Honoraria | $12,200 | 4 | 0.8% |
| Unspecified | $4,753 | 7 | 0.3% |
| Education | $109.14 | 4 | 0.0% |
Payments by Type
General
$1.4M
1,784 transactions
Research
$4,753
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $537,010 | 550 | $0 (2024) |
| Corcept Therapeutics | $357,431 | 362 | $0 (2024) |
| Merck Sharp & Dohme LLC | $213,545 | 264 | $0 (2022) |
| Novo Nordisk Inc | $150,090 | 226 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $80,710 | 115 | $0 (2024) |
| Eli Lilly and Company | $63,810 | 122 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $28,936 | 49 | $0 (2023) |
| Lilly USA, LLC | $8,369 | 59 | $0 (2024) |
| Mannkind Corporation | $4,429 | 6 | $0 (2020) |
| Novo Nordisk AS | $2,836 | 8 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $151,663 | 202 | Corcept Therapeutics ($95,981) |
| 2023 | $136,346 | 211 | Corcept Therapeutics ($62,206) |
| 2022 | $209,856 | 291 | Corcept Therapeutics ($93,944) |
| 2021 | $205,333 | 211 | Corcept Therapeutics ($103,149) |
| 2020 | $139,869 | 136 | AstraZeneca Pharmaceuticals LP ($82,952) |
| 2019 | $164,494 | 181 | AstraZeneca Pharmaceuticals LP ($107,529) |
| 2018 | $216,380 | 263 | AstraZeneca Pharmaceuticals LP ($114,140) |
| 2017 | $227,852 | 296 | AstraZeneca Pharmaceuticals LP ($108,245) |
All Payment Transactions
1,791 individual payment records from CMS Open Payments — Page 1 of 72
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Sequel Med Tech, LLC | — | Food and Beverage | In-kind items and services | $25.42 | General |
| 12/19/2024 | Eli Lilly and Company | MOUNJARO (Drug) | Travel and Lodging | Cash or cash equivalent | $46.90 | General |
| Category: Diabetes | ||||||
| 12/19/2024 | Eli Lilly and Company | MOUNJARO (Drug) | Travel and Lodging | Cash or cash equivalent | $36.00 | General |
| Category: Diabetes | ||||||
| 12/19/2024 | Eli Lilly and Company | MOUNJARO (Drug) | Travel and Lodging | Cash or cash equivalent | $1.75 | General |
| Category: Diabetes | ||||||
| 12/18/2024 | Corcept Therapeutics | Korlym (Drug) | Travel and Lodging | Cash or cash equivalent | $28.14 | General |
| Category: Endocrinology | ||||||
| 12/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $223.44 | General |
| 12/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $223.44 | General |
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $302.56 | General |
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $47.81 | General |
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $30.07 | General |
| 12/09/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: Diabetes | ||||||
| 11/26/2024 | Corcept Therapeutics | Korlym (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Endocrinology | ||||||
| 11/26/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $20.10 | General |
| Category: Diabetes | ||||||
| 11/21/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $88.54 | General |
| Category: Endocrinology | ||||||
| 11/20/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $117.57 | General |
| Category: Endocrinology | ||||||
| 11/20/2024 | Corcept Therapeutics | Korlym (Drug) | Travel and Lodging | Cash or cash equivalent | $55.58 | General |
| Category: Endocrinology | ||||||
| 11/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $517.71 | General |
| 11/08/2024 | Eli Lilly and Company | MOUNJARO (Drug) | Consulting Fee | Cash or cash equivalent | $4,950.00 | General |
| Category: Diabetes | ||||||
| 11/08/2024 | Eli Lilly and Company | MOUNJARO (Drug) | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| Category: Diabetes | ||||||
| 11/07/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Consulting Fee | Cash or cash equivalent | $2,875.00 | General |
| Category: Cardio-renal | ||||||
| 10/31/2024 | Corcept Therapeutics | Korlym (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Endocrinology | ||||||
| 10/30/2024 | Corcept Therapeutics | Korlym (Drug) | Travel and Lodging | Cash or cash equivalent | $90.42 | General |
| Category: Endocrinology | ||||||
| 10/30/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | Cash or cash equivalent | $12.53 | General |
| Category: Endocrinology | ||||||
| 10/25/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $9.53 | General |
| Category: Endocrinology | ||||||
| 10/24/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $47.50 | General |
| Category: Endocrinology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $2,813 | 1 |
| NN8022-4322 | Novo Nordisk Inc | $1,190 | 4 |
| Dario retrospective studies on Hba1c & HEOR outcomes | SANOFI-AVENTIS U.S. LLC | $750.00 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 159 | 310 | $125,777 | $17,750 |
| 2022 | 3 | 111 | 199 | $68,175 | $11,506 |
| 2021 | 3 | 95 | 168 | $61,070 | $10,355 |
| 2020 | 3 | 93 | 130 | $47,221 | $7,045 |
Total Patients
458
Total Services
807
Medicare Billing
$46,655
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 92 | 186 | $77,514 | $12,109 | 15.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 25 | $14,775 | $2,432 | 16.5% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 21 | 70 | $19,180 | $1,777 | 9.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 13 | $13,780 | $1,303 | 9.5% |
| 99421 | Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | Office | 2023 | 14 | 16 | $528.00 | $128.31 | 24.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 81 | 145 | $54,827 | $9,947 | 18.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 16 | 40 | $9,960 | $1,091 | 11.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 14 | 14 | $3,388 | $467.27 | 13.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 68 | 114 | $41,927 | $7,531 | 18.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 15 | 20 | $10,405 | $1,903 | 18.3% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 12 | 34 | $8,738 | $920.70 | 10.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 63 | 95 | $33,965 | $5,091 | 15.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 16 | 19 | $9,584 | $1,338 | 14.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 14 | 16 | $3,672 | $616.03 | 16.8% |
About Dr. Kevin Pantalone, D.O
Dr. Kevin Pantalone, D.O is a Endocrinology, Diabetes & Metabolism healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/06/2007. The National Provider Identifier (NPI) number assigned to this provider is 1922293547.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kevin Pantalone, D.O has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $151,663 received in 2024. These payments were reported across 1,791 transactions from 21 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.0M).
As a Medicare-enrolled provider, Pantalone has provided services to 458 Medicare beneficiaries, totaling 807 services with total Medicare billing of $46,655. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Cleveland, OH
- Active Since 09/06/2007
- Last Updated 02/25/2013
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1922293547
Products in Payments
- FARXIGA (Drug) $434,198
- Korlym (Drug) $357,431
- JANUVIA (Drug) $149,482
- BYDUREON (Drug) $93,087
- Kerendia (Drug) $57,137
- Ozempic (Drug) $56,519
- STEGLATRO (Drug) $34,415
- RYBELSUS (Drug) $19,822
- Xultophy 100/3.6 (Drug) $15,897
- Rybelsus (Drug) $14,464
- Tresiba (Drug) $12,141
- Non-Covered $11,223
- MOUNJARO (Drug) $10,628
- SOLIQUA (Drug) $8,763
- Victoza (Drug) $7,206
- AFREZZA (Drug) $4,429
- SOLIQUA 100/33 (Biological) $4,044
- SOTAGLIFLOZIN (Drug) $3,016
- TRULICITY (Drug) $2,109
- Saxenda (Drug) $1,923
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Cleveland
Adi Mehta, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $216,001
Endocrinology, Diabetes & Metabolism $216,001
Dr. Allan Kennedy, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $158,447
Endocrinology, Diabetes & Metabolism $158,447
Christian Nasr, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $152,638
Endocrinology, Diabetes & Metabolism $152,638
Dr. Bartolome Burguera, Md, Phd, MD, PHD
Endocrinology, Diabetes & Metabolism — Payments: $92,204
Endocrinology, Diabetes & Metabolism $92,204
Robert Zimmerman, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $58,659
Endocrinology, Diabetes & Metabolism $58,659
Marwan Hamaty, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $57,065
Endocrinology, Diabetes & Metabolism $57,065